GREY:ATBPF - Post by User
Post by
mstrmndon Oct 14, 2021 12:52pm
595 Views
Post# 34005721
Time to Market for H2S Pipeline
Time to Market for H2S PipelineThat's all that matters.
P2b/3a for OA to prove safety and efficacy for chronic use will be time and resource intensive.
P2b/3a for Post-Operative Pain for 10-14-day course of Otenaproxesul at 150 mg PO daily is ready to go with supporting AME data. Post-op mild LTE vs. GI ulcers, no one cares about 3-5x LTE in small subset especially when self-limiting because bigger concern is post-op DVT prophylaxis (particularly orthopedic surgeries) where incremental risk of GI bleeding with NSAIDs + DVT prophylaxis is a far worse outcome, and stopping prophylaxis due to bleeding is even worse.
Fast-track Otenaproxesul as a GI-safe opioid-sparring agent for mild-to-moderate post-operative pain as a preventative strategy for opioid addiction.
Once it's on the market, all subsequent INDs/CTAs will go faster. Overall this is a much better drug developement strategy imho. GLTA.